GNT Induction Treatment in Locally Advanced NPC
ConditionNasopharyngeal Carcinoma
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAir Force Military Medical University, China
About this trial
The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal carcinoma. It aims to answer whether gemcitabine, nimotuzumab and toripalimab as induction treatment show non-inferiority compared to GP induction chemotherapy. Participants will be randomly divided into two induction treatment groups.
Eligibility criteria
Qualifiers
Age 18 to 75 years old.
Pathologically or cytologically confirmed stage III-IVB nasopharyngeal keratinizing squamous cell carcinoma or non-keratinizing squamous cell carcinoma.
Patients suitable for radical radiochemotherapy.
ECOG PS score of 0-1.
Disqualifiers
Patients who have previously undergone immunotherapy or targeted therapy.
Participated in any other interventional clinical trials within 30 days before screening.
History of other malignancies (except for cured skin basal cell carcinoma).
History of primary immunodeficiency.
Trial design
Treatments tested in this trial
- gemcitabine,nimotuzumab, toripalimab
- gemcitabine, cisplatin
Treatment groups
228 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov